期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 13, 期 3, 页码 261-272出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0038
关键词
-
类别
资金
- Eisai
- Exelixis Inc.
- Bristol-Myers Squibb
- Genentech BioOncology
- Merck
- Novartis Oncology
- Novocure
- Boehringer Ingelheim Pharmaceuticals, Inc.
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据